Xyndari:

Withdrawal of the marketing authorisation application

glutamine

Overview

Emmaus Medical Europe Ltd withdrew its application for a marketing authorisation of Xyndari for the treatment of sickle cell disease. 

The company withdrew the application on 18 September 2019.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Xyndari (glutamine) (PDF/113.42 KB)


    First published: 18/10/2019
    EMA/521995/2019

  • Key facts

    Name
    Xyndari
    Product number
    EMEA/H/C/004734
    International non-proprietary name (INN) or common name
    • glutamine
    Active substance
    • glutamine
    Date of withdrawal
    18/09/2019
    Company making the application
    Emmaus Medical Europe Ltd
    Withdrawal type
    Initial authorisation

    All documents

    Related content

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating